ACURX PHARMACEUTICALS, INC. (ACXP)
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business